Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk

Atherosclerosis Supplements

Volumn 11, Issue 1, 2010, Pages 49-54

  Pallebage Gamarallage, Menuka M S ^a   Takechi, Ryusuke ^a   Lam, Virginie ^a   Galloway, Susan ^a   Dhaliwal, Satvinder ^a   Mamo, John C L ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; Amyloid beta; Blood brain barrier; Chylomicrons

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; IMMUNOGLOBULIN G; PRAVASTATIN; PROBUCOL; SATURATED FATTY ACID;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; EXTRAVASATION; FAT INTAKE; HUMAN; LIPID METABOLISM; MOUSE; NONHUMAN; PARENCHYMA; POSTPRANDIAL STATE; PRIORITY JOURNAL;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BLOOD-BRAIN BARRIER; CEREBROVASCULAR DISORDERS; CHOLESTEROL, DIETARY; CHYLOMICRONS; DEMENTIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MICE; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 77952584989     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2010.04.002     Document Type: Article

References (40)

1. Brookmeyer R., Johnson E., Ziegler-Graham K., et al. Forecasting the global burden of Alzheimer's disease. Alzheimer's Dimentia 3 3 (2007) 186-191
2. Kivipelto M., Helkala E.L., Laakso M.P., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322 (2001) 1447-1451
3. Skoog I., Kalaria R.N., and Breteler M.M.B. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 13 Suppl. 3 (1999) 106-114
4. Grant W.B. Dietary links to Alzheimer's disease. Alzheimer's Dis Rev 2 (1997) 42-55
5. Kalmijn S., Launer L.J., Ott A., et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Rev 42 (1997) 776-782
6. Barberger-Gateau P., Letenneur L., Deschamps V., et al. Fish, meat, and risk of dementia: cohort study. BMJ 325 (2002) 932-933
7. Morris M.C., Evans D.A., Bienias J.L., et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 60 (2003) 194-200
8. Kuo Y., Emmerling M., Bisgaier C., et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Ab 1-42 levels. Biochem Biophys Res Commun 252 (1998) 711-715
9. Zhang B., Matsunaga A., Saku K., et al. Associations among plasma lipoprotein subfractions as characterized by analytical capillary isotachophoresis, apolipoprotein E phenotype, Alzheimer disease, and mild cognitive impairment. Atheroscler Thromb Vasc Biol 24 8 (2004) e144-e146
10. Pastorino L., and Lu K.P. Pathogenic mechanisms in Alzheimer's disease. Eur J Pharmacol 545 1 (2006) 29-38
11. Crossgrove J.S., Li G.J., and Zheng W. The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. Exp Biol Med (Maywood) 230 10 (2005) 771-776
12. Deane R., Sagare A., Hamm K., et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25 (2005) 11495-11503
13. Donahue J., Flaherty S., Johanson C., et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112 (2006) 405-415
14. Thomas T., McLendon E.T., Sutton E., et al. Cerebrovascular endothelial dysfunction mediated by β-amyloid. NeuroReport 8 (1997) 1387-1391
15. Martel C.L., Mackica J.B., McComba J.G., et al. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. Neurosci Lett 206 2-3 (1996) 157-160
16. Zlokovic B.V., Ghiso J., Mackick J.B., et al. Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun 197 3 (1993) 1034-1040
17. George C., Arendash G., Kalaria R., et al. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res 818 (1999) 105-117
18. Galloway S., Jian L., Johnsen R., et al. β-Amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. J Nutr Biochem 18 (2007) 279-284
19. Mamo J.C.L., Jian L., James A.P., et al. Plasma lipoprotein beta amyloid in subjects with Alzheimer's disease and mild cognitive impairment. Ann Clin Biochem 45 (2008) 395-403
20. Smith D., Watts G.F., Dane-Stewart C., et al. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 29 3 (1999) 204-209
21. James A.P., Pal S., Gennat H.C., et al. The incorporation and metabolism of amyloid-beta into chylomicron-like lipid emulsions. J Alzheimers Dis 5 3 (2003) 179-188
22. Burges B.L., McIsaac S.A., Naus K.E., et al. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 24 1 (2006) 114-127
23. Salloway S., Gur T., Berzin T., et al. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. J Neurol Sci 203-204 (2002) 183-187
24. Zipser B., Johanson C., Gonzalez L., et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28 (2007) 977-986
25. Deane R., Sagare A., Hamm K., et al. apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J Clin Invest 118 12 (2008) 4002-4013
26. Takechi R., Galloway S., Pallebage-Gamarallage M., et al. Dietary fats, cerebrovasculature integrity and ALzheimer's disease risk. Prog Lipid Res 49 (2010) 159-170
27. Takechi R., Galloway S., Pallebage-Gamarallage M.M.S., et al. Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-b. Br J Nutr 103 (2010) 652-662
28. Bateman R.J., Wen G., Morris J.C., et al. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68 9 (2007) 666-669
29. Morgan N.G. Fatty acids and beta-cell toxicity. Curr Opin Clin Nutr Metab Care 12 2 (2009) 117-122
30. Diakogiannaki E., and Morgan N.G. Differential regulation of the ER stress response by long-chain fatty acids in the pancreatic beta-cell. Biochem Soc Trans 36 Pt 5 (2008) 959-962
31. Studzinski C.M., Li F., Bruce-Keller A.J., et al. Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in mice. J Neurochem 108 4 (2009) 860-866
32. Wassall S.R., Brzustowicz M.R., Shaikh S.R., et al. Order from disorder, corralling cholesterol with chaotic lipids. The role of polyunsaturated lipids in membrane raft formation. Chem Phys Lipids 132 1 (2004) 79-88
33. Wassall S.R., and Stillwell W. Polyunsaturated fatty acid-cholesterol interactions: domain formation in membranes. Biochim Biophys Acta 1788 1 (2009) 24-32
34. Dufouil C., Richard F., Fievet N., et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64 9 (2005) 1531-1538
35. Haag M.D., Hofman A., Koudstaal P.J., et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80 1 (2009) 13-17
36. Rosenberg P.B., Mielke M.M., Tschanz J., et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 16 11 (2008) 883-892
37. Kalayci R., Kaya M., Elmas I., et al. Effects of atrovastatin on blood-brain barrier permeability during l-NAME hypertension followed by angiotensin-II in rats. Brain Res 1042 (2005) 184-193
38. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 9 3 (2003) 94-101
39. Champagne D., Pearson D., Dea D., et al. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience 121 1 (2003) 99-110
40. Mamo J.C., Elsegood C.L., Umeda Y., et al. Effect of probucol on plasma clearance and organ uptake of chylomicrons and VLDLs in normal and diabetic rats. Arterioscler Thromb 13 2 (1993) 231-239